These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26247418)

  • 1. Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
    Tai SH; Agafitei O; Gao Z; Liggins R; Petric M; Withers SG; Niikura M
    Virus Res; 2015 Dec; 210():126-32. PubMed ID: 26247418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
    Abed Y; Nehmé B; Baz M; Boivin G
    Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
    Pizzorno A; Abed Y; Plante PL; Carbonneau J; Baz M; Hamelin MÈ; Corbeil J; Boivin G
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6398-405. PubMed ID: 25114143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
    McKimm-Breschkin JL; Barrett S; McKenzie-Kludas C; McAuley J; Streltsov VA; Withers SG
    Antiviral Res; 2019 Sep; 169():104542. PubMed ID: 31233807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
    Tewawong N; Vichiwattana P; Korkong S; Klinfueng S; Suntronwong N; Thongmee T; Theamboonlers A; Vongpunsawad S; Poovorawan Y
    PLoS One; 2017; 12(4):e0175655. PubMed ID: 28410396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
    Gohil DJ; Kothari ST; Shinde PS; Chintakrindi AS; Meharunkar R; Warke RV; Kanyalkar MA; Chowdhary AS; Deshmukh RA
    Infect Genet Evol; 2015 Jan; 29():75-81. PubMed ID: 25461259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Koch O; Seidel N; Schmidtke M; Clement B
    J Med Chem; 2014 Feb; 57(3):759-69. PubMed ID: 24422530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
    Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of influenza A(H1N1)/pdm2009, seasonal A(H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014.
    Liu SS; Jiao XY; Wang S; Su WZ; Jiang LZ; Zhang X; Ke CW; Xiong P
    Sci Rep; 2017 Aug; 7(1):8488. PubMed ID: 28814737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
    Brookes DW; Miah S; Lackenby A; Hartgroves L; Barclay WS
    J Antimicrob Chemother; 2011 Mar; 66(3):466-70. PubMed ID: 21172786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.